<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01894399</url>
  </required_header>
  <id_info>
    <org_study_id>HM-EMSI-102</org_study_id>
    <nct_id>NCT01894399</nct_id>
  </id_info>
  <brief_title>Study to Evaluate a Pharmacokinetic of HM61713 in Healthy Male Subjects</brief_title>
  <official_title>Phase I Study to Assess the Safety, Tolerability, Pharmacokinetic Characteristics of HM61713 Tablet in Healthy Korean, Japanese and Caucasian</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Hanmi Pharmaceutical Company Limited</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Hanmi Pharmaceutical Company Limited</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Study Design

        -  Open, escalating single-dose design.

        -  7 ascending dose cohorts

        -  In each cohorts, subjects will receive a single dose of HM61713.

        -  Main objective of this study is to evaluate the pharmacokinetics of HM61713 tablet.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Primary objectives

      • To assess the PK characteristics of HM61713 and metabolites in healthy male volunteers

      Secondary objectives

        -  To assess the safety and tolerability of HM61713 tablet in healthy male subjects.

        -  To assess the food effect on PK characteristics of HM61713 tablet in healthy male
           subjects.

        -  To assess the ethnic differences of PK characteristics of HM61713 (Korean, Japanese,
           Caucasian)

        -  To investigate genotype of drug metabolism.transport that affect PK characteristics of
           HM61713

        -  To investigate the change of endogenous metabolic markers after administration of
           HM61713
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>September 2013</start_date>
  <completion_date type="Actual">November 2013</completion_date>
  <primary_completion_date type="Actual">November 2013</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Maximum plasma concentration (Cmax) of HM61713 and metabolites</measure>
    <time_frame>0-48 hrs</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Area under the plasma concentration time curve from zero to infinity (AUC) of HM61713 and metabolites</measure>
    <time_frame>0-48 hrs</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Tmax of HM61713 and metabolites</measure>
    <time_frame>0-48 hrs</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Terminal half life (t1/2) of HM61713 and metabolites</measure>
    <time_frame>0-48 hrs</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>The apparent plasma clearance (CL/F) of HM61713 and metabolites</measure>
    <time_frame>0-48 hrs</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Mean residence time (MRT) of HM61713 and metabolites</measure>
    <time_frame>0-48 hrs</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Safety data, including physical examinations, laboratory evaluation, ECGs, ICGs, vital signs, and adverse events.</measure>
    <time_frame>7 days after the investigational drug administration.</time_frame>
  </secondary_outcome>
  <number_of_arms>7</number_of_arms>
  <enrollment type="Actual">59</enrollment>
  <condition>Healthy Volunteers</condition>
  <arm_group>
    <arm_group_label>Cohort 1</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>100 mg HM61713 single dose in Korean</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Cohort 2</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>200 mg HM61713 single dose in Korean</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Cohort 3</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>300 mg HM61713 single dose in Korean</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Cohort 4</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>200 mg HM61713 single dose in Japanese</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Cohort 5</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>300 mg HM61713 single dose in Japanese</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Cohort 6</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>200 mg HM61713 single dose in Caucasian</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Cohort 7</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>300 mg HM61713 single dose in Caucasian</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>HM61713</intervention_name>
    <description>Cohort 1 : 100mg single dose in Korean Cohort 2 : 200mg single dose in Korean Cohort 3 : 300mg single dose in Korean Cohort 4 : 200mg single dose in Japanese Cohort 5 : 300mg single dose in Japanese Cohort 6 : 200mg single dose in Caucasian Cohort 7 : 300mg single dose in Caucasian</description>
    <arm_group_label>Cohort 1</arm_group_label>
    <arm_group_label>Cohort 2</arm_group_label>
    <arm_group_label>Cohort 3</arm_group_label>
    <arm_group_label>Cohort 4</arm_group_label>
    <arm_group_label>Cohort 5</arm_group_label>
    <arm_group_label>Cohort 6</arm_group_label>
    <arm_group_label>Cohort 7</arm_group_label>
    <other_name>Olmutinib</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Healthy male volunteers, age between 20 and 45

          -  Informed of the investigational nature of this study and voluntarily agree to
             participate in this study

          -  BMI of ＞18.5kg/m2 and ＜28kg/m2 subject

        Exclusion Criteria:

          -  Use of any prescription medication within 2 weeks prior to Day 1

          -  Use of any medication within 1 weeks prior to Day 1

          -  Has a severe medical history of hypersensitivity to drug

          -  Participation in another clinical study within 8 weeks days prior to start of study
             drug administration
      </textblock>
    </criteria>
    <gender>Male</gender>
    <minimum_age>20 Years</minimum_age>
    <maximum_age>45 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>In-Jin Jang, MD PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Seoul National University Hospital</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Seoul</city>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Korea, Republic of</country>
  </location_countries>
  <verification_date>December 2016</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>July 3, 2013</study_first_submitted>
  <study_first_submitted_qc>July 3, 2013</study_first_submitted_qc>
  <study_first_posted type="Estimate">July 10, 2013</study_first_posted>
  <last_update_submitted>December 14, 2016</last_update_submitted>
  <last_update_submitted_qc>December 14, 2016</last_update_submitted_qc>
  <last_update_posted type="Estimate">December 15, 2016</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>HM61713</keyword>
  <keyword>pharmacokinetics</keyword>
  <keyword>Phase I</keyword>
  <keyword>healthy</keyword>
  <keyword>olmutinib</keyword>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

